RESUMO
Mature or peripheral T cell lymphomas [PTCL] are uncommon in most parts of the world and account for only 10-15% of all non-Hodgkin's lymphomas [NHLs]. They usually occur in middle-aged to elderly patients, 68% presenting with features characterized by a disseminated disease, with systemic symptoms in nearly half of them [45%], bone marrow [BM] involvement in a quarter [25.8%], andextranodal disease in a third [37%]. We report for the first time a patient with a lesion on the glans penis, an unusual site
RESUMO
This article presents the available data on Ximelagatran, a novel oral direct thrombin inhibitor and explores its therapeutic potential. Recent large clinical trials have evaluated the efficacy and safety of this anticoagulant compared to the standard anticoagulation therapy with warfarin and heparins in several thrombotic disorders. These trials provide strong evidence for the efficacy and safety of ximelagatran in the following clinical indications; the prevention of venous thromboembolism after knee or hip replacement, the treatment of deep venous thrombosis, and prevention of stroke in patients with atrial fibrillation. Further evaluation of this promising oral anticoagulant is warranted in other thrombotic cardiovascular disorders requiring chronic oral anticoagulation therapy such as in patients with prosthetic heart valves, intracardiac thrombi dilated cardiomyopathy, after myocardial infarction am post percutaneous coronary interventions
RESUMO
The study is aimed at determining the prevalence of HER2/neu overexpression in Qatari women with breast cancer and to assess the survival in patients with HER2/neu positive tumors. This is a retrospective study of clinical data of 70 Qatari female patients diagnosed with breast cancer during the period 1991 through to 2001, at Hamad Medical Corporation, Doha, Qatar. We also performed a retrospective review of breast tissue sample for those patients using paraffin sections and applying immunohistochemistry staining-[Hercep test [DAKO Inc]] to determine the HER2/neu status. Eighteen patients [26%] were HER2/neu positive [2+ and 3+] with a mean age at diagnosis of 49.3years, and 52 [74%] were negative [0 and 1+] with mean age at diagnosis of 46.6 years. Of the patients with positive HER2/neu, 5 [28%] had a relapse of the disease and 4 [22%] died of the disease during follow up. Of the patients with HER2/neu, negative test 9 [17%] had a relapse of the disease and 10 [19%] died of the disease. The median survival function at mean of covariates for HER2/neu positive patients was 26 months, and for HER2/NEU negative patients was 28 months. The prevalence of HER2/neu over expression in Qatari female with breast cancer in this study is 26%, but due to a small sample size it may not reflect really the prevalence. Patient with HER2/neu positive were older at diagnosis than patients with HER2/neu negative, also they had higher relapse rate and mortality. Median survival function was better for HER2/neu negative patients